Background
Methods
Original drug treatment model
Drug parameter | Artemether + lumefantrine | Dihydroartemisinin + piperaquine | |||
---|---|---|---|---|---|
AM | DHA | LF | DHA | PPQ | |
Vd (L/kg) | 46.6 (82) | 15 (48) | 21 (263) | 1.49 (48) | 150 (42) |
x (/day) | 23.98 (68) | – | – | – | – |
z (/day) | 11.97 (65) | – | – | – | – |
k (/day) | – | 44.15 (23) | 0.16 (5) | 19.8 (23) | 0.03 (54) |
IC50 (mg/L) | 0.0023 (79) | 0.009 (117) | 0.032 (102) | 0.009 (117) | 0.088 (30) |
Vmax | 27.6 | 27.6 | 3.45 | 27.6 | 3.45 |
n | 4 | 4 | 4 | 4 | 6 |
Integration of weight-for-age distribution of malaria endemic regions
Weight category | Age category | Number of tablets | ||||
---|---|---|---|---|---|---|
Drug | Global | Africa | Latin America | Asia | ||
AM-LF | 5–14 kg1 | 6 m–3 yrs | 6 m–3 yrs | 6 m–2 yrs | 6 m–3 yrs | 1 × 20/120 mg2 |
15–24 kg1 | 4–10 yrs | 4–9 yrs | 3–7 yrs | 4–11 yrs | 2 × 20/120 mg2 | |
25–34 kg1 | 11–14 yrs | 10–12 yrs | 8–10 yrs | 12–14 yrs | 3 × 20/120 mg2 | |
35 + kg1 | ≥15 yrs | ≥13 yrs | ≥11 yrs | ≥15 yrs | 4 × 20/120 mg2 | |
DHA-PPQ | 5– < 7 kg3 | 6 m–2 yrs | 6 m–1 yr | 6 m–1 yr | 6 m–2 yrs | 0.5 × 20/160 mg4 |
7– < 13 kg3 | 3–9 yrs | 2–8 yrs | 2–6 yrs | 3–10 yrs | 1 × 20/160 mg4 | |
13– < 24 kg3 | 10–14 yrs | 9–14 yrs | 7–11 yrs | 11–15 yrs | 1 × 40/320 mg4 | |
24– < 36 kg3 | ≥15 yrs | 15–19 yrs | 12–16 yrs | ≥16 yrs | 2 × 40/320 mg4 | |
36– < 75 kg3 | – | ≥20 yrs | ≥17 yrs | – | 3 × 40/320 mg4 | |
75–100 kg3 | – | – | – | – | 4 × 40/320 mg4 |
Sample size and follow-up time
Treatment scenarios
Results
Fully adherent patients
Number of tablets | Age-based dosing regimen | Weight-based dosing regimen | |||||||
---|---|---|---|---|---|---|---|---|---|
Global | Africa | Asia | Latin America | Global | Africa | Asia | Latin America | ||
1 × 20/120 mg | n | 1448 | 1448 | 1448 | 1063 | 2135 | 1848 | 2204 | 1455 |
AM below | 6.28% | 9.32% | 4.97% | 5.93% | 11.94% | 11.53% | 10.84% | 10.45% | |
AM above | 0.07% | 0.07% | 0.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
LF below | 26.66% | 31.63% | 23.90% | 27.85% | 46.60% | 43.99% | 45.78% | 43.44% | |
LF above | 11.05% | 10.64% | 11.53% | 6.49% | 7.35% | 8.17% | 8.35% | 4.74% | |
2 × 20/120 mg | n | 2781 | 2403 | 3216 | 2019 | 2497 | 2231 | 2585 | 1857 |
AM below | 2.45% | 2.25% | 2.52% | 1.78% | 0.00% | 0.00% | 0.00% | 0.00% | |
AM above | 0.22% | 0.17% | 0.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
LF below | 8.45% | 10.78% | 8.86% | 9.26% | 7.13% | 7.08% | 6.42% | 6.89% | |
LF above | 26.65% | 20.06% | 25.40% | 21.15% | 0.00% | 0.00% | 0.00% | 0.00% | |
3 × 20/120 mg | n | 1706 | 1270 | 1271 | 1147 | 1578 | 1307 | 1659 | 1206 |
AM below | 4.98% | 1.81% | 2.28% | 3.05% | 0.00% | 0.00% | 0.00% | 0.00% | |
AM above | 0.18% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
LF below | 13.07% | 9.06% | 9.76% | 10.99% | 0.00% | 0.00% | 0.00% | 0.00% | |
LF above | 17.76% | 15.04% | 11.49% | 15.69% | 0.00% | 0.00% | 0.00% | 0.00% | |
4 × 20/120 mg | n | 4065 | 4879 | 4065 | 5771 | 3790 | 4614 | 3552 | 5482 |
AM below | 8.83% | 24.78% | 2.44% | 34.21% | 9.55% | 26.16% | 2.48% | 35.94% | |
AM above | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
LF below | 26.17% | 57.45% | 14.42% | 66.14% | 28.94% | 60.71% | 17.23% | 69.66% | |
LF above | 1.62% | 2.46% | 2.07% | 2.41% | 0.00% | 0.00% | 0.00% | 0.00% |
Number of tablets | Age-based dosing regimen | Weight-based dosing regimen | |||||||
---|---|---|---|---|---|---|---|---|---|
Global | Africa | Asia | Latin America | Global | Africa | Asia | Latin America | ||
0.5 × 20/160 mg | n | 1037 | 657 | 1037 | 657 | 99 | 89 | 105 | 35 |
DHA below | 99.04% | 98.48% | 99.04% | 99.85% | 100.00% | 100.00% | 100.00% | 100.00% | |
DHA above | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
PPQ below | 99.04% | 98.48% | 99.04% | 99.85% | 100.00% | 100.00% | 100.00% | 100.00% | |
PPQ above | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
1 × 20/160 mg | n | 2836 | 2825 | 3222 | 2037 | 1343 | 1204 | 1401 | 1003 |
DHA below | 98.55% | 95.72% | 98.70% | 98.63% | 59.20% | 57.97% | 59.31% | 61.32% | |
DHA above | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
PPQ below | 98.55% | 95.72% | 98.70% | 98.63% | 59.20% | 57.97% | 59.31% | 61.32% | |
PPQ above | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
1 × 40/320 mg | n | 2005 | 2396 | 2053 | 1973 | 2946 | 2499 | 3063 | 2106 |
DHA below | 87.23% | 94.49% | 93.18% | 93.82% | 29.33% | 32.53% | 28.73% | 31.43% | |
DHA above | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
PPQ below | 87.23% | 94.49% | 93.18% | 93.82% | 29.33% | 32.53% | 28.73% | 31.43% | |
PPQ above | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
2 × 40/320 mg | n | 4122 | 2104 | 3688 | 2054 | 1908 | 1606 | 1990 | 1462 |
DHA below | 64.07% | 86.98% | 60.93% | 77.07% | 0.00% | 0.00% | 0.00% | 0.00% | |
DHA above | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
PPQ below | 64.07% | 86.98% | 60.93% | 77.07% | 0.00% | 0.00% | 0.00% | 0.00% | |
PPQ above | 0.05% | 0.00% | 0.00% | 0.15% | 5.56% | 6.79% | 5.48% | 5.54% | |
3 × 40/320 mg | n | 0 | 2018 | 0 | 3279 | 3686 | 4491 | 3441 | 5174 |
DHA below | – | 31.27% | – | 39.92% | 6.27% | 16.90% | 1.08% | 24.70% | |
DHA above | – | 0.00% | – | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
PPQ below | – | 31.27% | – | 39.92% | 6.27% | 16.90% | 1.08% | 24.70% | |
PPQ above | – | 0.05% | – | 0.00% | 5.18% | 2.58% | 6.02% | 2.11% | |
4 × 40/320 mg | n | 0 | 0 | 0 | 0 | 18 | 111 | 0 | 220 |
DHA below | – | – | – | – | 0.00% | 48.65% | – | 45.00% | |
DHA above | – | – | – | – | 0.00% | 0.00% | – | 0.00% | |
PPQ below | – | – | – | – | 0.00% | 48.65% | – | 45.00% | |
PPQ above | – | – | – | – | 0.00% | 0.00% | – | 0.00% |
Treatment scenario | Treatment outcome | Age-based dosing regimen | Weight-based dosing regimen | ||||||
---|---|---|---|---|---|---|---|---|---|
Global | Africa | Asia | Latin America | Global | Africa | Asia | Latin America | ||
Full course, i e, twice daily over three days at 0, 8, 24, 36, 48 and 60 hours | All parasites cleared | 99.83 | 99.81 | 99.83 | 99.81 | 99.83 | 99.82 | 99.85 | 99.82 |
Parasites below LoD | 0.01 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | |
Recrudescence | 0.15 | 0.16 | 0.15 | 0.16 | 0.15 | 0.15 | 0.13 | 0.15 | |
Parasites always above LoD | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Fifth dose missed | All parasites cleared | 99.78 | 99.75 | 99.77 | 99.68 | 99.79 | 99.75 | 99.78 | 99.68 |
Parasites below LoD | 0.01 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | |
Recrudescence | 0.20 | 0.22 | 0.21 | 0.29 | 0.19 | 0.22 | 0.20 | 0.29 | |
Parasites always above LoD | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Sixth dose missed | All parasites cleared | 99.78 | 99.75 | 99.77 | 99.68 | 99.79 | 99.75 | 99.78 | 99.68 |
Parasites below LoD | 0.01 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | |
Recrudescence | 0.20 | 0.22 | 0.21 | 0.29 | 0.19 | 0.22 | 0.20 | 0.29 | |
Parasites always above LoD | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Fifth and sixth dose missed | All parasites cleared | 99.52 | 99.39 | 99.55 | 99.24 | 99.56 | 99.4 | 99.53 | 99.24 |
Parasites below LoD | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | 0.02 | |
Recrudescence | 0.45 | 0.58 | 0.42 | 0.72 | 0.41 | 0.58 | 0.44 | 0.72 | |
Parasites always above LoD | 0.01 | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 | |
Third, fourth, fifth and sixth dose missed | All parasites cleared | 95.33 | 96.56 | 96.93 | 96.35 | 95.07 | 94.53 | 95.34 | 94.21 |
Parasites below LoD | 0.01 | 0.01 | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | |
Recrudescence | 4.50 | 3.30 | 2.92 | 3.48 | 4.75 | 5.21 | 4.50 | 5.53 | |
Parasites always above LoD | 0.16 | 0.13 | 0.12 | 0.15 | 0.17 | 0.25 | 0.15 | 0.26 | |
Third, fourth, fifth and sixth dose delayed by 12 hours | All parasites cleared | 99.83 | 99.82 | 99.83 | 99.81 | 99.83 | 99.83 | 99.85 | 99.82 |
Parasites below LoD | 0.01 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | |
Recrudescence | 0.15 | 0.15 | 0.15 | 0.16 | 0.15 | 0.14 | 0.13 | 0.15 | |
Parasites always above LoD | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Increased IC50 by 50-fold for LF and 10-fold for AM and DHA | All parasites cleared | 76.85 | 73.89 | 77.62 | 72.5 | 75.1 | 72.99 | 76.17 | 71.49 |
Parasites below LoD | 0.02 | 0.02 | 0.02 | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 | |
Recrudescence | 15.49 | 17.02 | 15.15 | 17.7 | 16.35 | 17.4 | 15.72 | 18.18 | |
Parasites always above LoD | 7.64 | 9.07 | 7.21 | 9.80 | 8.53 | 9.60 | 8.10 | 10.32 | |
Administered without food, i e, 50% lower dose for LF | All parasites cleared | 99.82 | 99.81 | 99.83 | 99.81 | 99.82 | 99.8 | 99.85 | 99.75 |
Parasites below LoD | 0.01 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | |
Recrudescence | 0.16 | 0.16 | 0.15 | 0.16 | 0.16 | 0.16 | 0.13 | 0.21 | |
Parasites always above LoD | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.02 |
Treatment scenario | Treatment outcome | Age-based dosing regimen | Weight-based dosing regimen | ||||||
---|---|---|---|---|---|---|---|---|---|
Global | Africa | Asia | Latin America | Global | Africa | Asia | Latin America | ||
Full course, i e, once daily over three days at 0, 24 and 48 hours | All parasites cleared | 90.53 | 91.03 | 90.33 | 92.21 | 97.73 | 97.49 | 97.78 | 97.36 |
Parasites below LoD | 0.40 | 0.47 | 0.36 | 0.40 | 0.41 | 0.38 | 0.40 | 0.46 | |
Recrudescence | 8.50 | 7.93 | 8.67 | 6.98 | 1.82 | 2.10 | 1.80 | 2.11 | |
Parasites always above LoD | 0.57 | 0.57 | 0.64 | 0.41 | 0.04 | 0.03 | 0.02 | 0.07 | |
Second dose missed | All parasites cleared | 69.24 | 69.75 | 68.32 | 72.70 | 90.68 | 89.7 | 91.06 | 88.8 |
Parasites below LoD | 0.50 | 0.55 | 0.54 | 0.45 | 0.52 | 0.60 | 0.49 | 0.65 | |
Recrudescence | 24.01 | 23.73 | 24.68 | 21.92 | 8.13 | 8.91 | 7.76 | 9.59 | |
Parasites always above LoD | 6.25 | 5.97 | 6.46 | 4.93 | 0.67 | 0.79 | 0.69 | 0.96 | |
Third dose missed | All parasites cleared | 70.46 | 71.16 | 69.83 | 74.02 | 91.2 | 90.34 | 91.61 | 89.48 |
Parasites below LoD | 0.50 | 0.50 | 0.48 | 0.44 | 0.48 | 0.58 | 0.45 | 0.62 | |
Recrudescence | 24.28 | 23.76 | 24.75 | 22.01 | 7.77 | 8.45 | 7.45 | 9.16 | |
Parasites always above LoD | 4.76 | 4.58 | 4.94 | 3.53 | 0.55 | 0.63 | 0.49 | 0.74 | |
Second and third dose missed | All parasites cleared | 27.06 | 27.64 | 26.04 | 30.01 | 51.90 | 49.55 | 52.23 | 48.77 |
Parasites below LoD | 0.32 | 0.31 | 0.32 | 0.34 | 0.61 | 0.47 | 0.59 | 0.44 | |
Recrudescence | 31.06 | 31.02 | 31.37 | 31.53 | 31.25 | 31.91 | 31.42 | 31.63 | |
Parasites always above LoD | 41.56 | 41.03 | 42.27 | 38.12 | 16.24 | 18.07 | 15.76 | 19.16 | |
Second and third dose delayed by 24 hours | All parasites cleared | 89.80 | 90.18 | 89.48 | 91.55 | 97.62 | 97.36 | 97.65 | 97.19 |
Parasites below LoD | 0.44 | 0.47 | 0.41 | 0.40 | 0.41 | 0.40 | 0.44 | 0.47 | |
Recrudescence | 8.96 | 8.54 | 9.29 | 7.42 | 1.93 | 2.20 | 1.88 | 2.24 | |
Parasites always above LoD | 0.80 | 0.81 | 0.82 | 0.63 | 0.04 | 0.04 | 0.03 | 0.10 |
Adherence scenarios
Drug resistance scenarios
Time to recrudescence
Treatment scenario | Age-based dosing regimen | Weight-based dosing regimen | |||||||
---|---|---|---|---|---|---|---|---|---|
Full course, i e, twice daily over three days at 0, 8, 24, 36, 48 and 60 hours | Min. | 14 | 12 | 14 | 11 | 14 | 12 | 14 | 11 |
1st Qu. | 22 | 19 | 24 | 18 | 22 | 19 | 24 | 18 | |
Median | 29 | 27 | 31 | 28 | 29 | 28 | 30 | 28 | |
Mean | 33 | 31 | 34 | 30 | 31 | 31 | 31 | 29 | |
3rd Qu. | 46 | 46 | 48 | 44 | 41 | 43 | 38 | 38 | |
Max. | 57 | 53 | 58 | 52 | 57 | 53 | 56 | 52 | |
Fifth dose missed | Min. | 10 | 8 | 10 | 8 | 10 | 8 | 10 | 8 |
1st Qu. | 17 | 14 | 19 | 20 | 17 | 17 | 19 | 20 | |
Median | 30 | 28 | 30 | 35 | 25 | 28 | 28 | 36 | |
Mean | 30 | 30 | 31 | 32 | 30 | 31 | 32 | 33 | |
3rd Qu. | 44 | 45 | 46 | 43 | 46 | 46 | 47 | 43 | |
Max. | 54 | 59 | 55 | 57 | 54 | 59 | 57 | 57 | |
Sixth dose missed | Min. | 10 | 8 | 10 | 8 | 10 | 8 | 10 | 8 |
1st Qu. | 17 | 14 | 19 | 20 | 17 | 17 | 19 | 20 | |
Median | 30 | 28 | 30 | 35 | 25 | 28 | 28 | 36 | |
Mean | 30 | 30 | 31 | 32 | 30 | 31 | 32 | 33 | |
3rd Qu. | 44 | 44 | 45 | 43 | 46 | 46 | 46 | 43 | |
Max. | 54 | 59 | 55 | 57 | 54 | 59 | 56 | 57 | |
Fifth and sixth dose missed | Min. | 6 | 5 | 7 | 5 | 6 | 5 | 7 | 5 |
1st Qu. | 25 | 28 | 22 | 27 | 19 | 28 | 22 | 27 | |
Median | 35 | 38 | 33 | 38 | 37 | 37 | 36 | 38 | |
Mean | 33 | 35 | 33 | 36 | 33 | 34 | 33 | 35 | |
3rd Qu. | 43 | 45 | 43 | 45 | 43 | 45 | 44 | 45 | |
Max. | 62 | 61 | 62 | 60 | 62 | 61 | 59 | 60 | |
Third, fourth, fifth and sixth dose missed | Min. | 3 | 5 | 5 | 3 | 3 | 4 | 3 | 3 |
1st Qu. | 19 | 21 | 23 | 21 | 19 | 18 | 18 | 18 | |
Median | 26 | 30 | 31 | 29 | 25 | 25 | 25 | 24 | |
Mean | 27 | 30 | 31 | 30 | 26 | 26 | 26 | 25 | |
3rd Qu. | 34 | 39 | 39 | 38 | 34 | 33 | 34 | 32 | |
Max. | 61 | 61 | 63 | 63 | 61 | 63 | 61 | 63 | |
Third, fourth, fifth and sixth dose delayed by 12 hours | Min. | 14 | 12 | 14 | 11 | 14 | 12 | 14 | 11 |
1st Qu. | 22 | 19 | 24 | 18 | 22 | 18 | 24 | 18 | |
Median | 29 | 26 | 31 | 29 | 29 | 27 | 30 | 28 | |
Mean | 33 | 30 | 34 | 30 | 32 | 29 | 31 | 29 | |
3rd Qu. | 46 | 40 | 48 | 44 | 41 | 38 | 38 | 38 | |
Max. | 57 | 54 | 58 | 52 | 57 | 54 | 56 | 52 | |
Increased IC50 by 50-fold for LF and 10-fold for AM and DHA | Min. | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
1st Qu. | 15 | 14 | 15 | 14 | 15 | 14 | 14 | 14 | |
Median | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | |
Mean | 21 | 21 | 21 | 20 | 21 | 21 | 21 | 20 | |
3rd Qu. | 27 | 27 | 27 | 26 | 26 | 26 | 26 | 26 | |
Max. | 51 | 57 | 51 | 62 | 54 | 57 | 55 | 55 | |
Administered without food, i e, 50% lower dose for LF | Min. | 11 | 12 | 14 | 11 | 11 | 9 | 12 | 8 |
1st Qu. | 20 | 19 | 24 | 18 | 20 | 19 | 15 | 18 | |
Median | 25 | 27 | 31 | 28 | 23 | 28 | 24 | 29 | |
Mean | 28 | 31 | 34 | 30 | 27 | 29 | 27 | 30 | |
3rd Qu. | 39 | 46 | 48 | 44 | 34 | 40 | 34 | 41 | |
Max. | 52 | 53 | 58 | 52 | 52 | 48 | 52 | 49 |
Treatment scenario | Age-based dosing regimen | Weight-based dosing regimen | |||||||
---|---|---|---|---|---|---|---|---|---|
Full course, i e, once daily over three days at 0, 24 and 48 hours | Min. | 5 | 5 | 5 | 5 | 7 | 6 | 5 | 6 |
1st Qu. | 18 | 17 | 18 | 19 | 25 | 25 | 25 | 26 | |
Median | 25 | 25 | 26 | 27 | 34 | 34 | 34 | 32 | |
Mean | 27 | 27 | 27 | 28 | 36 | 35 | 35 | 33 | |
3rd Qu. | 35 | 35 | 35 | 36 | 47 | 45 | 46 | 41 | |
Max. | 63 | 62 | 63 | 63 | 63 | 63 | 63 | 63 | |
Second dose missed | Min. | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
1st Qu. | 13 | 14 | 14 | 14 | 21 | 21 | 22 | 21 | |
Median | 23 | 23 | 22 | 23 | 29 | 29 | 29 | 29 | |
Mean | 24 | 24 | 24 | 25 | 31 | 30 | 31 | 30 | |
3rd Qu. | 33 | 32 | 32 | 33 | 40 | 38 | 39 | 37 | |
Max. | 63 | 63 | 63 | 63 | 62 | 63 | 63 | 63 | |
Third dose missed | Min. | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
1st Qu. | 12 | 13 | 13 | 13 | 21 | 20 | 21 | 20 | |
Median | 22 | 22 | 21 | 22 | 29 | 29 | 29 | 29 | |
Mean | 23 | 23 | 23 | 23 | 30 | 29 | 30 | 29 | |
3rd Qu. | 31 | 31 | 31 | 32 | 39 | 38 | 39 | 37 | |
Max. | 63 | 63 | 63 | 63 | 63 | 63 | 63 | 63 | |
Second and third dose missed | Min. | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
1st Qu. | 7 | 7 | 7 | 7 | 12 | 11 | 12 | 11 | |
Median | 15 | 15 | 15 | 16 | 21 | 21 | 22 | 21 | |
Mean | 19 | 18 | 18 | 19 | 23 | 22 | 23 | 22 | |
3rd Qu. | 28 | 27 | 28 | 28 | 32 | 31 | 32 | 31 | |
Max. | 63 | 63 | 63 | 63 | 63 | 63 | 63 | 63 | |
Second and third dose delayed by 24 hours | Min. | 6 | 6 | 6 | 6 | 7 | 6 | 7 | 8 |
1st Qu. | 18 | 18 | 19 | 20 | 25 | 25 | 24 | 25 | |
Median | 26 | 27 | 27 | 28 | 34 | 34 | 34 | 33 | |
Mean | 27 | 28 | 28 | 29 | 36 | 35 | 35 | 33 | |
3rd Qu. | 35 | 36 | 36 | 37 | 48 | 45 | 47 | 41 | |
Max. | 63 | 63 | 63 | 63 | 63 | 63 | 63 | 63 |